CDC Works 24/7
•87% Informative
Outbreak is associate the Food and Drug Administration on FDA including eye infections.
Three products have been voluntarily recalled by their manufacturer, Global Pharma (Chennai, India), in association with this outbreak.
EzriCare Artificial Tears was the only common art Verona l tears product identified across four heal Guiana facility clusters.
The infect VIM-GES-CRPA sed by a strain of carbapenem- the United States ginosa that produces the Verona integron-encoded metallo--lactamase (VIM) A subset of 5 isolates that underwent antimicrobial susceptibility testi EzriCare efiderocol were susceptible to this agent.
Bacteriophage CDC hage) FDA th activity clinicians he outbreak strain have been identifi EzriCare Artificial Tears 3 wit two laVIM-80 and blaGES-9 is resistant to imipenem or me Delsam Pharma’s Artificial Tears that Delsam Pharma’s e Artificial Ointment S) and identify CDC Aerug FDA s ST1201 wi clinicians osa are encouraged to rep EzriCare s to Delsam Pharma’s Artificial Tears are-associated infections program contact. CDC an cl FDA =" Clinicians d_highLightText__NxlGi">Delsam Pharma’s A Pseudomonas aeruginosa ts CRPA an> VIM-CRPA htText__NxlGi">FDA Alert January 1, 2022 xt__NxlGi">2023 February 3, 2023 February May 15, 2023 sp CDC class="summaryFeed_highLightText__NxlGi">2023 81 aryFeed_highL 18 htText__N CA Gi CO Fe CT ua DE 2 FL /s IL n> NC NJ n NM as NV "s NY ma OH Fe PA _h SD hL TX htText WA Nx WI i">2023 VIM-GES-CRPA an class="summaryFeed_highLightText__NxlGi">March 1, 13 tText__NxlGi">March 14, 2023 13 s="summaryF 6 ed 46% ghLightText__NxlGi">Updates the February 2, 2023 yFeed_highLightText__NxlGi">CDC blaGES-9 blaVIM-80 WGS 7 maryFeed_highLightText__NxlGi">the Antimicrobial Resistance Laboratory Network VIM-CRPA CRPA May 2022 to April 2023 ext__NxlGi">the Antimicrobial Resistance Laboratory Network 14 Text__NxlGi">Isolates 21 highLightT 13 t__NxlGi">meropenem < 3 pan class= 3 summaryFeed_ 1 ighLightText__NxlGi">imipe 26 m P. aeruginosa Contact Precautions14 n> an additional 4 _NxlGi">Enhanced Barrier Precautions 4 ryFeed_highLigh 30 days NxlG VIM-GES-CRPA /span> Contact Precautions 10 yFeed_highLightText__NxlGi">VIM-CRPA EzriCare Artificial Tears CRPA VIM-CRPA 2 four ="summaryFeed_highLightText__NxlGi">Organisms CDC pan class="summaryFeed_highL VIM-GES-CRPA lGi">Januar EzriCare 2 VIM-CRPA two lGi">CRPA VIM-GES-CRPA an class="summaryFeed_highLightText__NxlGi">Antimicrobial Resistance Laboratory NetworkEzriCare Artificial Tears yFee FDA ighLightText__NxlGi">VIM-CRPA P. Three an class="summaryFeed_highLightText__NxlGi">Healthcare < Global Pharma ummaryFeed_ India ightText__NxlGi">VIM-GES-CRPA EzriCare Artificial Tears hi Delsam Pharma Artificial Tears Delsam Pharma Artificial Ointment ightText__NxlGi">CDC 3 EzriCare Artificial Tears c Delsam Pharma Artificial Tears t__Nxl Delsam Pharma Artificial Ointment ry FDA d_highLightText__NxlGi">Delsam Pharma’s Artificial Ointment De FDA m Pharma’s Artificial Tears EzriCare
VR Score
89
Informative language
90
Neutral language
70
Article tone
formal
Language
English
Language complexity
88
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links